Skip to main content

Buy Jounce For A Bounce

Jounce Therapeutics announced it will present data at the ASCO conference for its candidate JTX-2011, and the Street interpreted the abstract negatively. We see this selloff as an overreaction, and one we can take a gamble on.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.